Fundraising FoxSamsara BioCapital — 2020 Investments
7 investments dated 2020 · listed companies and verified rows first · show all
Neurogene develops gene therapy treatments for rare neurological diseases.
BiotechDeep TechDigital HealthLongevityMedical DevicesNew York, US
Rachel McMinn(Founder and Chief Executive Officer)inRachel McMinn, Ph.D.(Founder and Chief Executive Officer)
BoardCory Freedland(Director)inStephen Biggar(Director)
Board seatRobert Baffi· per SEC Form D
Co-investorsEcoR1 CapitalCasdin CapitalREDMILERTW Investments L.P.William Blair
A2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform, supporting both autologous and allogeneic applications.
BiotechDeep TechDigital HealthHealthtechMedical DevicesAgoura Hills, US
C. Alexander Kamb(Director)inJim Robinson(CEO)inScott Foraker(Executive Officer, Director)Madhavan Balachandran(Director)Michael Gallo(Director)
Board seatSrini Akkaraju· per SEC Form D
Co-investorsMana VenturesNextech InvestThe Column GroupVida Ventures
IonPath develops MIBIscope, a spatial proteomics platform that uses multiplexed ion beam imaging to simultaneously measure dozens of protein targets in preserved tissue samples for translational research and discovery.
BiotechDeep TechMedical Devices
Co-investorsHemisphere Ventures LLCNorwich VenturesVertical Venture Partners
BiotechFremont, US
Avanish Vellanki(Executive Officer)in
Co-investorsBiotechnology Value FundJanus Henderson Investors
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)inBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
BoardAaron Royston(Director)in
Co-investorsLifeSci Venture PartnersScion Life SciencesSofinnova VenturesTCG CrossovervenBio PartnersVersant Ventures+4 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Graphite Bio, Inc.Palladio Biosciences
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.